8:30-9:00 a.m.

Opening Remarks

9:00-9:45 a.m.

“Statin Deniers: Death and Disability by Disinformation”

Sir Rory Collins, FRS, FMedSci
Head of Department and BHF Professor of Medicine and Epidemiology, Nuffield Department of Population Health, Oxford University

9:45-10:30 a.m.

“From reading the genome for risk to rewriting it for cardiovascular health”

Sekar Kathiresan, M.D., Ph.D.
CEO, Verve Therapeutics

10:30-10:45 a.m.

Break

10:45-11:30 a.m.

“On the cell biology of cholesterol esterification”

Elina Ikonen, M.D., Ph.D.
Professor, Department of Anatomy, University of Helsinki

11:30 a.m.-12:15 p.m.

“Advancing genomic medicine for cardiometabolic disease”

Daniel J. Rader, M.D.
Chief, Division of Translational Medicine and Human Genetics, Perelman School of Medicine

12:15-1:00 p.m.

Lunch

1:00-1:45 p.m.

“The power of tracer kinetic studies for characterization of lipid and lipoprotein disorders”

Henry Ginsberg, M.D.
Irving Professor of Medicine, Columbia University Irving Medical Center

1:45-2:30 p.m.

“Metabolically healthy and unhealthy obesity”

Sam Klein, M.D.
Division Chief, Nutritional Science & Obeesity Medicine, Washington University School of Medicine

2:30-2:45 p.m.

Break

2:45-3:30 p.m.

“GPIHBP1, LPL, and Intravascular Triglyceride Metabolism”

Stephen G. Young, M.D.
Distinguished Professor of Medicine and Human Genetics, University of California Los Angeles

3:30-4:15 p.m.

“Regulation of Intravascular Lipid Metabolism by ANGPTL3/4/8 Proteins and APOA5”

Robert Konrad, M.D.
Senior Vice President, Eli Lilly and Company

4:15-4:30 p.m.

Closing Remarks